Product Code: RP-ID-10325231 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10325231
Market Overview:
Global Cancer Monoclonal Antibodies Market Size study, by Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies), by Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others), by Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others) and Regional Forecasts 2020-2027
Global Cancer Monoclonal Antibodies Market is valued at approximately USD 41.3 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 11.3% over the forecast period 2020-2027. Cancer monoclonal antibodies is a type of laboratory-produced molecules which is being serve as substitute antibodies that can improve, restore, or simulate the immune system's raid on cancer cells. They are primarily intended to bind to antigens which are usually more in the amount on the surface of cancer cells than healthy cells. They can be used in the treatment of several types of cancer, including brain cancer, breast cancer, lung cancer, melanoma, and many more, thus accelerating the growth of cancer monoclonal antibodies market around the world. Further, increasing prevalence of cancer, rising investments & funding in research & development of genomic studies, and technological enhancements in genetic sequencing and target gene selection are the few factors responsible for the high CAGR of the market during the forecast period. Cancer is the one of the major causes of death around the world. According to the International Agency for Research on Cancer (IARC), in 2018, there were around 17.0 million new cancer cases and 9.5 million cancer deaths registered throughout the world. Also, the prevalence of cancer around the world is expected to grow to almost 27.5 million new cancer cases and 16.3 million cancer deaths by the year 2040. This, in turn, is expected to augment the demand for cancer monoclonal antibodies around the world. Amidst the COVID-19 outbreak around the world, the pharma industry is more concerned about the development of the COVID-19 vaccine, thus, R&D efforts for cancer monoclonal antibodies is substantially decline. Though, the demand for cancer monoclonal antibodies is not affecting, and it is high as much as before the COVID-19 crisis. Therefore, the market will boost at a significant rate in the upcoming years. However, stringent regulatory guidelines and long duration of R&D with rising failures in clinical trials are the few factors impeding the market growth during the forecast period of 2020-2027.
The regional analysis of the global Cancer Monoclonal Antibodies market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the increasing cases of cancer among people, along with the rising government expenditure for infection control and management in the region. Whereas, North America is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as rising government funding for cancer research & technology, followed by the availability of a significant number of market players would create lucrative growth prospects for the Cancer Monoclonal Antibodies market across the Asia-Pacific region.
Major market player included in this report are:
Amgen Inc.
Bristol Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Genmab AS
GlaxoSmithKline PLC
Johnson & Johnson
Novartis AG
Merck & Co., Inc
Spectrum Pharmaceuticals Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Murine Antibodies
Chimeric Antibodies
Humanized Antibodies
By Therapies:
Bevacizumab (Avastin)
Rituximab (Rituxan)
Trastuzumab (Herceptin)
Cetuximab (Erbitux)
Panitumumab (Vectibix)
Others
By Application:
Breast Cancer
Blood Cancer
Liver Cancer
Brain Cancer
Colorectal Cancer
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027
Target Audience of the Global Cancer Monoclonal Antibodies Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Amgen Inc.
Bristol Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Genmab AS
GlaxoSmithKline PLC
Johnson & Johnson
Novartis AG
Merck & Co., Inc
Spectrum Pharmaceuticals Inc.
Related Reports
Proof of Quality & Reliability
